CNBP researchers get commercialisation grants

19 December 2016:

CNBP researchers Prof Rob McLaughlin (pictured) and Dr Erik Schartner, have received funding for their research activity through the University of Adelaide’s Commercial Accelerator Scheme.

Through CAS, the University contributes up to $400,000 each year in cash to research projects with a commercial application. The funding is provided for proof of concept and early commercialisation activities, to promote translational research for impact, and greater industry engagement.

Funding details follow below, with additional information available online.

Smart needles for safer and more effective brain surgery
$80,000 awarded to Professor Rob McLaughlin (Adelaide School of Medicine and ARC Centre of Excellence for Nanoscale BioPhotonics )
A novel miniaturised imaging probe, so small that it can be encased within a hypodermic needle for use in neurosurgery, enables safer and more effective brain biopsies. Having already progressed this product to initial human in vivo studies, this high-tech medical device is ready to go through the regulatory pathways. If commercialised, it could service an estimated $200m market, creating new employment opportunities in South Australia, and better neurosurgery outcomes globally.

Cancer cell detector
$80,000 awarded to Dr Erik Schartner (School of Physical Sciences and ARC Centre of Excellence for Nanoscale BioPhotonics)
With 15-20% of breast cancer surgery patients requiring additional surgery to further remove tumorous tissue, there is a need for improved surgical practices that can also provide enhanced cosmetic outcomes. This technology offers a novel detection tool using optical fibre sensors that will differentiate between cancerous and normal tissues based on pH levels, to provide specific, real-time information to surgeons.